Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence.
Journal
Current opinion in rheumatology
ISSN: 1531-6963
Titre abrégé: Curr Opin Rheumatol
Pays: United States
ID NLM: 9000851
Informations de publication
Date de publication:
01 05 2021
01 05 2021
Historique:
pubmed:
21
3
2021
medline:
28
9
2021
entrez:
20
3
2021
Statut:
ppublish
Résumé
Several new therapeutic drugs are now available for the management of rheumatoid arthritis (RA). Given that RA has been associated with an increased risk of certain cancers like lymphoma and lung cancer, concern remains about the safety of (newer) immunosuppressants used in RA management as it relates to the risk of cancer. Most meta-analyses of randomized clinical trials of tumor necrosis factor inhibitors (TNFi) have not observed an association between TNFi and risk of incident cancer. Studies of non-TNFi biologic disease modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs and cancer are also reassuring but limited and of short-term follow-up. Regarding the use of DMARDs in patients with RA and a prior malignancy, retrospective studies have shown that TNFi use is not associated with recurrence. There is a need for ongoing studies on the safety of non-TNFi bDMARDs and targeted synthetic disease modifying anti-rheumatic drugs and recurrent cancer. Further research is also needed to guide the patients, rheumatologists, and oncologists regarding the safest DMARDs to choose for patients with RA and a recent diagnosis of cancer.
Identifiants
pubmed: 33741804
doi: 10.1097/BOR.0000000000000796
pii: 00002281-202105000-00012
doi:
Substances chimiques
Antirheumatic Agents
0
Biological Products
0
Tumor Necrosis Factor Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
292-299Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther 2015; 17:212.
Smitten AL, Simon TA, Hochberg MC, et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008; 10:R45.
Fragoulis GE, Chatzidionysiou K. Lung cancer in rheumatoid arthritis. Is there a need for better risk assessment and screening? Clin Rheumatol 2020; 39:957–961.
Sugiyama D, Nishimura K, Tamaki K, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2010; 69:70–81.
Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54:692–701.
Elandt K, Aletaha D. Treating rheumatic patients with a malignancy. Arthritis Res Ther 2011; 13:223.
Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA 2018; 320:1360–1372.
Sparks JA. Rheumatoid Arthritis. Ann Intern Med 2019; 170:ITC1–ITC16.
Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295:2275–2285.
Leombruno JP, Einarson TR, Keystone EC. The safety of antitumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009; 68:1136–1145.
Dreyer L, Mellemkjaer L, Andersen AR, et al. Incidences of overall and site specific cancers in TNFalpha inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry. Ann Rheum Dis 2013; 72:79–82.
Mercer LK, Galloway JB, Lunt M, et al. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2017; 76:497–503.
Solomon DH, Kremer JM, Fisher M, et al. Comparative cancer risk associated with methotrexate, other nonbiologic and biologic disease-modifying antirheumatic drugs. Semin Arthritis Rheum 2014; 43:489–497.
Mercer LK, Regierer AC, Mariette X, et al. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Ann Rheum Dis 2017; 76:2025–2030.
Singh N, Gao Y, Field E, et al. Trends of lymphoma incidence in US veterans with rheumatoid arthritis. RMD Open 2020; 6:
Hellgren K, Di Giuseppe D, Smedby KE, et al. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype. Rheumatology 2020.
Nikiphorou E, Buch MH, Hyrich KL. Biologics registers in RA: methodological aspects, current role and future applications. Nat Rev Rheumatol 2017; 13:503–510.
Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011; 70:1895–1904.
Haynes K, Beukelman T, Curtis JR, et al. Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum 2013; 65:48–58.
Mercer LK, Lunt M, Low AL, et al. Risk of solid cancer in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2015; 74:1087–1093.
Wadstrom H, Frisell T, Askling J. Anti-Rheumatic Therapy in Sweden Study G. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: A Nationwide Cohort Study From Sweden. JAMA Intern Med 2017; 177:1605–1612.
Kim SC, Pawar A, Desai RJ, et al. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: a multidatabase cohort study. Semin Arthritis Rheum 2019; 49:222–228.
Montastruc F, Renoux C, Dell’Aniello S, et al. Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study. Rheumatology 2019; 58:683–691.
Ozen G, Pedro S, Schumacher R, et al. Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study. Arthritis Res Ther 2019; 21:141.
Simon TA, Boers M, Hochberg M, et al. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multidatabase real-world study. Arthritis Res Ther 2019; 21:228.
Simon TA, Soule BP, Hochberg M, et al. Safety of abatacept versus placebo in rheumatoid arthritis: integrated data analysis of nine clinical trials. ACR Open Rheumatol 2019; 1:251–257.
de Germay S, Bagheri H, Despas F, et al. Abatacept in rheumatoid arthritis and the risk of cancer: a world observational postmarketing study. Rheumatology 2020; 59:2360–2367.
Welsh MM, Applebaum KM, Spencer SK, et al. CTLA4 variants, UV-induced tolerance, and risk of nonmelanoma skin cancer. Cancer Res 2009; 69:6158–6163.
Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155–164.
Xie W, Yang X, Huang H, et al. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: a meta-analysis of observational studies. Semin Arthritis Rheum 2020; 50:930–937.
Emery P, Furst DE, Kirchner P, et al. Risk of malignancies in patients with rheumatoid arthritis treated with rituximab: analyses of global postmarketing safety data and long-term clinical trial data. Rheumatol Ther 2020; 7:121–131.
Maloney DG. Preclinical and phase I and II trials of rituximab. Semin Oncol 1999; 26: (5 Suppl 14): 74–78.
McLaughlin P, White CA, Grillo-Lopez AJ, Maloney DG. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology 1998; 12:1763–1769. discussion 1769-1770, 1775-1767.
Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res 2016; 68:1–25.
Honda S, Harigai M. The safety of baricitinib in patients with rheumatoid arthritis. Expert Opin Drug Saf 2020; 19:545–551.
Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open 2020; 6:
Smolen JS, Genovese MC, Takeuchi T, et al. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol 2019; 46:7–18.
Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis 2020.
Wang F, Sun L, Wang S, et al. Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. Mayo Clin Proc 2020; 95:1404–1419.
Pfizer shares co-primary endpoint results from post-marketing required safety study of Xeljanz® (Tofacitinib) in subjects with rheumatoid art. 2021.
Cappelli LC, Shah AA. The relationships between cancer and autoimmune rheumatic diseases. Best Pract Res Clin Rheumatol 2020; 34:101472.
Dreyer L, Cordtz RL, Hansen IMJ, et al. Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study. Ann Rheum Dis 2018; 77:510–514.
Phan H, Weideman RA, Cipher DJ, Feagins LA. Safety of tumor necrosis factor inhibitor use in patients with concomitant malignancy. Intest Res 2020; 18:282–288.
Phillips C, Zeringue AL, McDonald JR, et al. Tumor necrosis factor inhibition and head and neck cancer recurrence and death in rheumatoid arthritis. PLoS One 2015; 10:e0143286.
Pundole X, Zamora NV, Siddhanamatha H, et al. Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapy. Clin Rheumatol 2020.
Raaschou P, Frisell T, Askling J, et al. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 2015; 74:2137–2143.
Raaschou P, Soderling J, Turesson C, et al. Tumornecrosis factor inhibitors and cancer recurrence in swedish patients with rheumatoid arthritis: A Nationwide Population-Based Cohort Study. Ann Intern Med 2018; 169:291–299.
Mamtani R, Clark AS, Scott FI, et al. Association between breast cancer recurrence and immunosuppression in rheumatoid arthritis and inflammatory bowel disease: a cohort study. Arthritis Rheumatol 2016; 68:2403–2411.
Pappas DA, Rebello S, Liu M, et al. Therapy with biologic agents after diagnosis of solid malignancies: results from the corrona registry. J Rheumatol 2019; 46:1438–1444.
Pundole X, Zamora NV, Siddhanamatha H, et al. Utilization of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and cancer. Clin Rheumatol 2020; 39:787–794.